Clinical trials: Immunity, Humoral
Yellow Fever
Complementary Study of the Duration of Post-vaccination Against Yellow Fever Immunity in Children
In a previous study by the researchers' group, the researchers' investigate the duration of yellow fever post-vaccination immunity in vaccinated children between 9 and 23 months of age.
- Trial name
- NCT02990182
- Where
- Brazil
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Oswaldo Cruz Foundation
Ebola Virus Disease
PREVAIL VI: Identification of Host Genetic Factors Underlying Ebola Virus Disease Risk, Mortality, Long-term Sequelae, Viral RNA Persistence, Humoral Immunity, and Ebola Vaccine Response
Background: Genes are instructions that tell the body how to work and grow. They can affect how the body responds to infection. Researchers want to learn more about genes that affect how the body responds to the Ebola virus.
- Trial name
- NCT03098862
- Where
- 4 sites in Liberia
- Volunteers
- 4,830 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID, SARS-CoV-2
Antibody Detection in COVID-19 Cured Patients (SARS-CoV-2-CZ-Immunity)
The aim of the SARS-CoV-2-CZ-Immunity study is to determine the time profile of the presence of antibodies against SARS-CoV-2 in blood plasma by quantification of antibodies or performing a rapid test in COVID-19 cured patients.
- Trial name
- SARSCoV2CZImun (NCT04453280)
- Testing
- Quantitative analysis of anti-SARS-CoV-2-antibodies, SARS-CoV-2 diagnostic rapid test
- Where
- Czechia
- Volunteers
- 695 people
- Sponsor
- Institute of Health Information and Statistics of the Czech Republic
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia
Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TAR
This research study is for subjects that are receiving a bone marrow transplant. As part of the transplant subjects will receive stem cells from a donor who has agreed to donate stem cells for them.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome
- Trial name
- TAR (NCT01611298)
- Testing
- Tetanus
- Where
- 2 sites in United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Robert Krance
Monkeypox
A Phase 2 Randomized Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for Mpox
This study is a Phase 2 open-label, non-placebo controlled, multi-site clinical trial that will evaluate the standard SC regimen in adolescents ages 12 through 17 years, inclusive, and compared to the standard subcutaneous…
- Trial name
- NCT05740982
- Testing
- JYNNEOS
- Where
- 18 sites in United States, Puerto Rico
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Covid19, Immunosuppression
Humoral and Cellular Immune Response to COVID-19 Vaccines in Immunocompromised and Healthy Individuals
Currently, the efficacy of COVID-19 vaccination in immunodeficient patients is unknown. Here the investigators aim to evaluate the efficacy of COVID-19 vaccines in immunodeficient patients compared to healthy controls.
- Trial name
- CoVVac (NCT04858607)
- Testing
- Blood sample, Saliva sample
- Where
- Austria
- Volunteers
- 373 people, healthy volunteers welcome
- Sponsor
- Medical University of Graz
Sickle Cell Disease
Monocytic Expression of Heme Oxidase-1 (HO-1) in Sickle Cell Patients and Correlation With the Humoral Immune Response to Vaccine and With Allo-immunization.
Sickle cell disease (SCD) is an autosomal recessive disorder resulting from a substitution in the β chain of hemoglobin (Hb) which causes hemoglobin S to polymerize when deoxygenated.
- Trial name
- NCT03111589
- Testing
- Inactivated influenza A (H1N1) virus vaccine, Blood sampling
- Where
- 2 sites in Belgium
- Volunteers
- 102 people
- Sponsor
- Francis Corazza
Healthy
Studies of In Vitro B Lymphocyte Responses in Subjects Receiving Tetanus Toxoid Booster Immunization
One of the major interests of this laboratory is the characterization of the cellular subpopulations involved in the triggering and immunoregulation of B lymphocytes to produce antibodies.
- Trial name
- NCT00001173
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Gut Microbiota, Skin Microbiota
Lactobacillus Rhamnosus GG: Interaction With Human Microbiota and Immunity
Hypothesis: Probiotics have been used as novel adjunct therapeutic approach in atopic dermatitis. In addition to balancing the gut microecology and promoting host immune defences, specific probiotics might further aid in…
- Conditions
- Gut Microbiota, Skin Microbiota, Humoral Immune Responses, Severity of Atopic Dermatitis
- Trial name
- NCT01148667
- Testing
- Casein hydrolysate added with LGG, Infants drink casein hydrolysate without LGG
- Where
- Finland
- Volunteers
- 40 people
- Sponsor
- Turku University Hospital
COVID-19
Assessment of Incidence of SARS-CoV-2 Infection and COVID-19 in Brazil (AVISA)
This is an observational study, meaning that no interventions is tested, to determine incidence of SARS-CoV-2 infection and COVID-19 in different clinical sites in Brazil in several age groups.
- Trial name
- AVISA (NCT04355338)
- Where
- 11 sites in Brazil
- Volunteers
- 3,520 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
Immunologic Deficiency Syndromes, Neoplasms
Studies of the Immune Response in Normal Subjects and Patients With Disorders of the Immune System
The goal of the protocol is to define the normal humoral and cellular immune responses to antigens in volunteers and to define abnormalities of these immune responses in patients with immunodeficiency diseases or cancer.
- Trial name
- NCT00001158
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Poliomyelitis
Intestinal and Humoral Immunity of Sequential Polio Vaccination Schedules
This is a phase IV open-label randomized clinical trial that will compare intestinal and humoral immunity in infants receiving inactivated poliovirus vaccine (IPV) and two or three doses of bivalent oral poliovirus vaccine (bOPV).
- Trial name
- NCT02412514
- Testing
- bOPV (three dose), bOPV (two dose), IPV
- Where
- Bangladesh
- Volunteers
- 456 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Chronic Kidney Disease 5D, Chronic Kidney Disease 5T
Humoral and Cellular İmmune Response to SARS-CoV-2 mRNA BNT162b2 Vaccine in Children With Chronic Kidney Diseases
Coronavirus 2019 (COVID-19) infection is associated with higher morbidity and mortality in adult patients on dialysis, and kidney transplant recipients (KTRs).
- Trial name
- NCT05465863
- Testing
- SARS-CoV-2 mRNA BNT162b2 vaccine (Pfizer-BioNTech®)
- Where
- 6 sites in Turkey (Türkiye)
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Istanbul University - Cerrahpasa
Seasonal Influenza, Influenza
Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects
This study aims to evaluate the immunogenicity, by means of cell mediated immunity (CMI) and hemagglutination inhibition (HI) assay, and also the safety of a MF59C.1-adjuvanted subunit influenza vaccine compared with a…
- Conditions
- Seasonal Influenza, Influenza, Influenza Due to Unspecified Influenza Virus, Human Influenza
- Trial name
- NCT01342796
- Testing
- MF59C.1-adjuvanted subunit influenza vaccine, Sub unit, Inactivated, Influenza vaccine
- Where
- 2 sites in Belgium
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Atherosclerosis, Chlamydia Infections
Effects of Hormone Therapy on the Immune Systems of Postmenopausal Women With Chronic Infections
Hardening of the arteries (atherosclerosis) and heart disease are much more common in men than in women. However, as women grow older, especially after menopause the incidence of atherosclerosis and heart disease increases.
- Conditions
- Atherosclerosis, Chlamydia Infections, Cytomegalovirus Infections, Pneumonia, Bacterial
- Trial name
- NCT00001890
- Testing
- Estrogen therapy
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Food Allergy, Egg Protein Allergy
Immune Responses in Hen's Egg Oral Immunotherapy
The study determines how a 6 months oral immunotherapy (OIT) program with hen's egg (HE) effects cellular and humoral immune responses in 50 children with HE allergy.
- Conditions
- Food Allergy, Egg Protein Allergy, Immune Tolerance
- Trial name
- NCT03744325
- Testing
- Hen's egg OIT
- Volunteers
- 50 people
- Sponsor
- Helsinki University Central Hospital
Pneumonia, Pneumococcal Infections
Humoral Determinants of Immunity to Pneumococcal Infection
The purpose of this study is to determine whether there are differences in the level of antibody to capsular polysaccharides of S.
- Conditions
- Pneumonia, Pneumococcal Infections, Infections, Streptococcus Pneumoniae
- Trial name
- NCT00304382
- Testing
- Prevnar, Pneumovax
- Where
- United States
- Volunteers
- 114 people
- Sponsor
- VA Office of Research and Development
Humoral Immune Response
Study to Evaluate Safety and Pharmacokinetics of BIVIGAM® in Primary Immune Deficiency Subjects Aged 2 to 16
This study is part of the BIVIGAM® post marketing requirement (PMR). It is being conducted in subjects aged 2-16 with primary immune deficiency disorders associated with defects in humoral immunity to generate additional data on…
- Trial name
- NCT03164967
- Testing
- Bivigam
- Where
- 8 sites in United States
- Volunteers
- 16 people
- Sponsor
- ADMA Biologics, Inc.
SARS-CoV-2
Analysis of the Inflammatory Response and the Development of Humoral and Cellular Immunity in Patients With COVID-19
The SARS-CoV-2 infection in the airway epithelium induces cytopathic effects and the cessation of ciliary movement. Increased cytokines and chemokines have been reported to be associated with the severity of the disease.
- Trial name
- NCT04423640
- Testing
- Active COVID-19 disease
- Where
- Mexico
- Volunteers
- 200 people
- Sponsor
- Coordinación de Investigación en Salud, Mexico
Primary Immune Deficiency Disorder
Pharmacokinetics, Efficacy, and Safety Study of RI-002 (IGIV) in Subjects With Primary Immunodeficiency Diseases (PIDD)
This is a Phase III, multicenter, open-label study of RI-002 administered as an intravenous infusion of RI-002 (IGIV) every 21 or 28 days in approximately 60 subjects with Primary Immunodeficiency Diseases (PIDD).
- Trial name
- NCT01814800
- Testing
- RI-002
- Where
- 9 sites in United States
- Volunteers
- 59 people
- Sponsor
- ADMA Biologics, Inc.